Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 5/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5755963 | 0.95 | DDB1 (0.57) | DDB1CRBNPOLBHSD11B1CTSD | |
| Hydrochloric Acid SCHEMBL15650706 | 0.93 | DDB1 (0.55) | DDB1CRBNPOLBHSD11B1CTSD | |
| SCHEMBL837901 | 0.88 | DDB1 (0.60) | DDB1CRBNPOLBHSD11B1CTSD | |
| SCHEMBL5755256 | 0.84 | PSEN1 (0.46) | DDB1CRBNPOLBCTSDPSEN1 | |
| SCHEMBL31300159 | 0.84 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8186635 | 0.82 | ESR1 (0.48) | DDB1CRBN | |
| SCHEMBL7174784 | 0.82 | CTSD (0.47) | CTSD | |
| SCHEMBL28025688 | 0.80 | PSEN1 (0.49) | CRBNPOLBPSEN1PSEN2APH1B | |
| SCHEMBL6979837 | 0.80 | POLB (0.51) | DDB1CRBNPOLBHSD11B1CTSD | |
| SCHEMBL27551339 | 0.79 | EPHX1 (0.40) | CRBNPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105026409-B | Monokaryon ruthenium complex and the organic synthesis for having used the monokaryon ruthenium complex | 国立大学法人九州大学 | 2018-12-11 | — | — | CN | disclosed |
| CN-103102519-B | Rubber composition for tire tread and use its pneumatic tire | 横滨橡胶株式会社 | 2018-06-01 | — | — | CN | disclosed |
| CN-105026410-B | Monokaryon iron complex and the organic synthesis for having used the monokaryon iron complex | 国立大学法人九州大学 | 2018-04-17 | — | — | CN | disclosed |
| CN-105722909-B | Pneumatic tire | 住友橡胶工业株式会社 | 2018-04-06 | — | — | CN | disclosed |
| EP-2632900-A2 | CAPROLACTAM MGLUR5 RECEPTOR MODULATORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130203735-A1 | CAPROLACTAM MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2013-08-08 | — | — | US | disclosed |
| WO-2012058128-A2 | CAPROLACTAM MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| EP-1885775-A1 | ENHANCING INTERACTIVITY BETWEEN AMINE-FUNCTIONALIZED POLYMERS AND PARTICULATE FILLERS | Bridgestone Corporation (JP) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006128158-A1 | ENHANCING INTERACTIVITY BETWEEN AMINE-FUNCTIONALIZED POLYMERS AND PARTICULATE FILLERS | BRIDGESTONE CORPORATION (JP) | 2006-11-30 | — | — | WO | disclosed |
| EP-0821674-B1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | SEARLE & CO (US) | 2003-08-06 | — | — | EP | disclosed |
| US-6043261-A | TREATMENT OF INFLAMMATORY CONDITIONS AFFECTING THE JOINTS, FOR EXAMPLE ARTHRITIS, INFLAMMATORY BOWEL DISEASE, CARDIOVASCULAR ISCHEMIA, DIABETES, HYPERALGESIA, CEREBRAL ISCHEMIA, THROMBOTIC STROKE, GLOBAL ISCHEMIA, NERVOUS SYSTEM DISORDERS | G. D. SEARLE & CO. (US) | 2000-03-28 | — | — | US | disclosed |
| US-6011028-A | Cyclic amidino agents useful as nitric oxide synthase inhibitors | G.D. SEARLE & CO. (US) | 2000-01-04 | — | — | US | disclosed |
| US-5883251-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5776983-A | ANTIDIABETIC AGENTS, OBESITY, GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0821674-A1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033175-A1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-10-24 | — | — | WO | disclosed |
| EP-0659737-A2 | Catecholamine surrogates useful as B3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
| US-5190958-A | Fungicides | SHELL RESEARCH LIMITED (GB) | 1993-03-02 | — | — | US | disclosed |
| EP-0435387-A1 | Piperidine derivatives | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1991-07-03 | — | — | EP | disclosed |
| EP-0354377-A2 | Process for the preparation of aromatic polyether ketones | BAYER AG (DE) | 1990-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203735-A1 | CAPROLACTAM MGLUR5 RECEPTOR MODULATORS | GRM5, GRIK5, GRM1 | DDB1 3827/4885CRBN 2958/4885POLB 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.